Investor
GSK plc
CIK 0001131399 · filed 2026-05-14 · SEC filing
13F book
$599.2M
Positions
13
0 new · 2 sold
Largest name
25.6%
Crispr Therapeutics Ag · CRSP
Est. mark
−$199.8M
Price effect on 13 names still held. Flow −$67.4K.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Crispr Therapeutics Ag | CRSP | 3.22M | $153.2M | 25.6% | −$15.7M | Held |
| Wave Life Sciences Ltd. | WVE | 18.2M | $132.3M | 22.1% | −$177.9M | Held |
| Biontech Se | BNTX | 889.8K | $79.1M | 13.2% | −$5.62M | Held |
| Vir Biotechnology, Inc. | VIR | 8.55M | $76.6M | 12.8% | $25.1M | Held |
| IDEAYA Biosciences, Inc. | IDYA | 1.33M | $44.4M | 7.4% | −$1.67M | Held |
| Lyell Immunopharma, Inc. | LYEL | 1.51M | $30.3M | 5.1% | −$16.2M | Held |
| Cytokinetics Inc | CYTK | 340.4K | $22.4M | 3.7% | $806.8K | Held |
| Spero Therapeutics, Inc. | SPRO | 9.19M | $21.5M | 3.6% | $91.9K | Held |
| Fulcrum Therapeutics, Inc. | FULC | 1.79M | $13.7M | 2.3% | −$6.5M | Held |
| CVRx, Inc. | CVRX | 1.01M | $9.53M | 1.6% | $2.38M | Held |
| Bicycle Therapeutics Plc | BCYC | 1.53M | $7.1M | 1.2% | −$3.73M | Held |
| Nkarta, Inc. | NKTX | 3.15M | $6.65M | 1.1% | $819.2K | Held |
| REGENXBIO Inc. | RGNX | 271.5K | $2.27M | 0.4% | −$1.63M | Held |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.